MX358785B - Hemoglobina pegilada reticulada con diaspirina. - Google Patents

Hemoglobina pegilada reticulada con diaspirina.

Info

Publication number
MX358785B
MX358785B MX2014011763A MX2014011763A MX358785B MX 358785 B MX358785 B MX 358785B MX 2014011763 A MX2014011763 A MX 2014011763A MX 2014011763 A MX2014011763 A MX 2014011763A MX 358785 B MX358785 B MX 358785B
Authority
MX
Mexico
Prior art keywords
diaspirin
pegylated hemoglobin
crosslinked pegylated
diaspirin crosslinked
hemoglobin
Prior art date
Application number
MX2014011763A
Other languages
English (en)
Spanish (es)
Other versions
MX2014011763A (es
Inventor
D Vandegriff Kim
Malavalli Ashok
D Olsen Scott
Original Assignee
Sangart Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sangart Inc filed Critical Sangart Inc
Publication of MX2014011763A publication Critical patent/MX2014011763A/es
Publication of MX358785B publication Critical patent/MX358785B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C04B35/634—Polymers
    • C04B35/63448—Polymers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • C04B35/63488—Polyethers, e.g. alkylphenol polyglycolether, polyethylene glycol [PEG], polyethylene oxide [PEO]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/105831—Protein or peptide standard or control [e.g., hemoglobin, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
MX2014011763A 2012-03-29 2013-03-15 Hemoglobina pegilada reticulada con diaspirina. MX358785B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261617639P 2012-03-29 2012-03-29
PCT/US2013/032694 WO2013148375A1 (en) 2012-03-29 2013-03-15 Diaspirin crosslinked pegylated hemoglobin

Publications (2)

Publication Number Publication Date
MX2014011763A MX2014011763A (es) 2015-08-07
MX358785B true MX358785B (es) 2018-09-04

Family

ID=49261107

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014011763A MX358785B (es) 2012-03-29 2013-03-15 Hemoglobina pegilada reticulada con diaspirina.

Country Status (10)

Country Link
US (1) US10029001B2 (cg-RX-API-DMAC7.html)
EP (1) EP2830638B1 (cg-RX-API-DMAC7.html)
JP (2) JP2015514086A (cg-RX-API-DMAC7.html)
KR (1) KR102144139B1 (cg-RX-API-DMAC7.html)
CN (2) CN109731098A (cg-RX-API-DMAC7.html)
AU (1) AU2013240141B2 (cg-RX-API-DMAC7.html)
CA (1) CA2908236C (cg-RX-API-DMAC7.html)
HK (1) HK1207560A1 (cg-RX-API-DMAC7.html)
MX (1) MX358785B (cg-RX-API-DMAC7.html)
WO (1) WO2013148375A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3233803T (lt) * 2014-12-19 2019-04-10 Aragon Pharmaceuticals, Inc. Diariltiohidantoino junginio gamybos būdas
CN105017515A (zh) * 2015-07-20 2015-11-04 湖南华腾制药有限公司 聚乙二醇修饰物的制备方法
CN106421805B (zh) * 2016-09-14 2019-06-04 中国人民解放军军事医学科学院野战输血研究所 一种右旋糖酐交联血红蛋白氧载体及其制备方法与应用
EP3655019A4 (en) 2017-07-18 2021-04-21 Virtech Bio, Inc. BLOOD SUBSTITUTES INCLUDING HEMOGLOBIN AND METHODS OF MANUFACTURING
US11857605B2 (en) 2021-03-01 2024-01-02 Billion King International Limited Thiosuccinyl-crosslinked hemoglobin conjugates and methods of use and preparation thereof
CN114146165B (zh) * 2021-12-02 2022-08-12 润方(北京)生物医药研究院有限公司 一种聚合血红蛋白在制备防治呼吸衰竭药物中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4529719A (en) * 1983-05-04 1985-07-16 Tye Ross W Modified crosslinked stroma-free tetrameric hemoglobin
EP0206448B1 (en) * 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
CA1312009C (en) 1986-11-10 1992-12-29 Carl W. Rausch Extra pure semi-synthetic blood substitute
US5234903A (en) 1989-11-22 1993-08-10 Enzon, Inc. Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute
US5585484A (en) 1995-04-19 1996-12-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Hemoglobin crosslinkers
US6627738B2 (en) 1995-09-15 2003-09-30 Duke University No-modified hemoglobins and uses therefor
US7019117B2 (en) 2001-07-19 2006-03-28 Albert Einstein College Of Medicine Of Yeshiva University Size enhanced hemoglobins: surface decoration and crosslinking of the protein with polyoxy alkylene glycols
US20050164915A1 (en) * 2002-04-01 2005-07-28 Sangart, Inc. Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
US20030153491A1 (en) 2002-01-11 2003-08-14 Winslow Robert M. Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
US7144989B2 (en) 2002-03-25 2006-12-05 Albert Einstein College Of Medicine Of Yeshiva University Pegylated non-hypertensive hemoglobins, methods of preparing same, and uses thereof
AU2003299700B2 (en) 2002-12-23 2009-03-26 Albert Einstein College Of Medicine Of Yeshiva University Modified hemoglobin and methods of making same
KR100512483B1 (ko) 2003-05-07 2005-09-05 선바이오(주) 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법
DE602005023191D1 (de) * 2004-08-31 2010-10-07 Sangart Inc Verfahren zur verbesserung der hämodynamischen stabilität mit sauerstoff-tragenden zusammensetzungen
EP1863503B1 (en) 2005-03-07 2019-05-22 Sangart, Inc. Composition for delivering carbon monoxide (co) and nitric ozide (no) co to tissue using heme proteins as carriers
WO2006135740A1 (en) 2005-06-10 2006-12-21 Albert Einstein College Of Medicine Of Yeshiva University Pegylated hemoglobin and albumin and uses thereof
US7504377B2 (en) * 2006-10-23 2009-03-17 Ikor, Inc. Nitric oxide-blocked cross-linked tetrameric hemoglobin
WO2011106396A1 (en) 2010-02-25 2011-09-01 Sangart, Inc. Methods for preparing peg-hemoglobin conjugates using reduced reactant ratios
US20130052232A1 (en) * 2011-08-31 2013-02-28 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking

Also Published As

Publication number Publication date
AU2013240141A1 (en) 2014-11-13
JP2015514086A (ja) 2015-05-18
JP6668515B2 (ja) 2020-03-18
JP2019089789A (ja) 2019-06-13
EP2830638B1 (en) 2021-05-05
AU2013240141B2 (en) 2017-11-02
CN104379160A (zh) 2015-02-25
KR20150009533A (ko) 2015-01-26
CN109731098A (zh) 2019-05-10
MX2014011763A (es) 2015-08-07
KR102144139B1 (ko) 2020-08-12
HK1207560A1 (en) 2016-02-05
CA2908236C (en) 2021-10-26
WO2013148375A1 (en) 2013-10-03
US10029001B2 (en) 2018-07-24
US20150087590A1 (en) 2015-03-26
EP2830638A1 (en) 2015-02-04
EP2830638A4 (en) 2015-12-16
CA2908236A1 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
EP4582090A3 (en) Composition comprising pegylated arginine deiminase
MX2013006100A (es) Agente terapeutico que induce citotoxicidad.
CA2908236C (en) Diaspirin crosslinked pegylated hemoglobin
WO2014191359A9 (en) Aptamers and use of the aptamers in the diagnosis and treatment of cancer
IN2014DN09782A (cg-RX-API-DMAC7.html)
PH12013500899A1 (en) Modified factor ix polypeptides and uses thereof
EA201101522A1 (ru) Способы лечения болезней с использованием эпиметаболического переключателя (коэнзим q10)
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
PH12013500082B1 (en) Formulations of rifaximin and uses thereof
NZ700073A (en) Combination therapy with an anti - hyaluronan agent and a tumor - targeted taxane
MY177242A (en) Imidazopyrrolidinone compounds
PH12014501639A1 (en) Pharmaceutical compositions and methods
MX2011008383A (es) Agonistas basados en acido ribonucleico sintetico de receptor 7 tipo toll.
GB201020860D0 (en) Disulfiram formulation and uses thereof
PH12012501814A1 (en) Fe(iii) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias
WO2013061083A3 (en) Therapeutic agents and uses thereof
WO2009105585A3 (en) Postsynaptically targeted chemodenervation agents and their methods of use
WO2009095261A3 (en) Vaccine compositions
MX342313B (es) Peptidos a base de lactoferrina humana que tienen actividad antiinflamatoria.
WO2011153431A3 (en) Peripheral blood sparc antibodies and uses thereof
WO2009135165A3 (en) Small humanin-like peptides
MX348412B (es) Métodos de usar sns-595 para el tratamiento de sujetos con cáncer con actividad reducida de brca2.
WO2012090207A3 (en) Par1 and par2 c-tail peptides and peptide mimetics
EP4361634A3 (en) Methods for treating and monitoring the status of cancer
WO2008148932A3 (en) Glycosylasparaginase for treatment of cancers or inflammatory diseases

Legal Events

Date Code Title Description
FG Grant or registration